ArticleBMC psychiatry2025
Lipidomic analyses reveal the dysregulation of oxidized fatty acids (OxFAs) and acyl-carnitines (CARs) in major depressive disorder: a case-control study.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The LPC-ATX-LPA-LPAR Axis in Major Depressive Disorder: From PC/LPC Metabolism to Receptor-Active Lipid Signaling.International journal of molecular sciences · 2026Review
- Cross-Platform and cross-species lipidomic profiling identifies promising biomarkers for adolescent major depressive disorder.Molecular psychiatry · 2026Article
- Amino Acid-Fatty Acid Profile as a Novel Predictive Method in the Assessment of Diagnosis and Treatment Efficacy of Anxiety-Related Disorders and Mood Disorders.International journal of molecular sciences · 2026Review
- Article
- Ceramides and neuroinflammation as immunometabolic drivers and biomarkers of major depressive disorder, treatment-resistant depression, and suicidal vulnerability.Frontiers in pharmacology · 2026Review
- Lipid metabolism dysregulation in late-life depression: peripheral metabolic disturbance, central lipid alterations, and dietary modulation.Frontiers in nutrition · 2026Review
- Gender specific associations and interactions of fat quality with sleep and mental health in the elderly.Journal of health, population, and nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGrowing data indicated that individuals diagnosed with major depressive disorder (MDD) had widespread inflammation, oxidative stress, and metabolic dysregulation. The objective of our study was to detect alterations in lipids of individuals with MDD, with the ultimate aim of developing potential biomarkers that may contribute to the diagnosis and treatment of MDD.
methodsThe current study was a single-center cross-sectional case-control design. Serum samples were obtained from 107 individuals diagnosed with MDD and 97 healthy controls (HC) aged 18 to 60 years. Lipidomics analysis was performed using an Ultimate 3000 UHPLC system coupled with a Q-Exactive HF MS platform. All data were processed using the specialized online software Metaboanalyst 5.0.
resultsBased on the filtering criteria of false discovery rate (FDR) -adjusted P < 0.05, variable importance in projection (VIP) > 1.5, and fold change (FC) > 2.0 or < 0.5, a total of 40 lipids were identified as significantly different. In patients with MDD, we observed an increase in 11 types of oxidized fatty acids (OxFAs) and a decrease in 5 types of OxFAs. Additionally, we found that 8 types of acyl-carnitines (CARs) decreased, primarily comprising singular carbon chain structures, while 3 types of CARs increased, all with numerical carbon chain patterns. Lipid profiles yield a high area under the receiver operating characteristic (ROC) curve for differentiating MDD, with the most prominent ROC ranking being mostly attributed to OxFAs.
conclusionsOur research found significant variations in lipid levels, specifically increased OxFAs and decreased CARs, in individuals with MDD compared to HCs. Supplementation with PUFAs and acyl-carnitines warrants further investigation as a potential strategy for the management of MDD. Nevertheless, further investigation is necessary, and exercise prudence is required when examining and implementing their forms and proportions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.